Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb: Enfamil infant formula drives U.S. nutritionals sales up 5% to $267 mil. in the second quarter, Bristol reports July 28. The product also spurred international nutritionals results up 10% to $281 mil. to lead worldwide nutritionals business to $548 mil. in total revenues, up 7% over the prior-year period. The unit was a strong performer for Bristol's overall business, which recorded relatively flat sales of $4.9 bil. and an 89% increase in net earnings to $991 mil. The company's consumer medicines sales declined 16% to $57 mil.; Bristol recently announced plans to divest the unit to Novartis, a transaction expected to close by the end of the third quarter (1"The Tan Sheet" July 18, 2005, p. 3)...
You may also be interested in...
Novartis Purchase Of Bristol OTCs Has Excedrin Written All Over It
Novartis will enter the U.S. over-the-counter analgesics market with Excedrin as part of the purchase of Bristol-Myers Squibb's OTC portfolio
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands